Immunogenicity of a DNA vaccine candidate for COVID-19

Trevor R. F. Smith, Ami Patel, Stephanie Ramos, Dustin Elwood, Xizhou Zhu, Jian Yan, Ebony N. Gary, Susanne N. Walker, Katherine Schultheis, Mansi Purwar, Ziyang Xu, Jewell Walters, Pratik Bhojnagarwala, Maria Yang, Neethu Chokkalingam, Patrick Pezzoli, Elizabeth Parzych, Emma L. Reuschel, Arthur Doan, Nicholas Tursi, Miguel Vasquez, Jihae Choi, Edgar Tello-Ruiz, Igor Maricic, Mamadou A. Bah, Yuanhan Wu, Dinah Amante, Daniel H. Park, Yaya Dia, Ali Raza Ali, Faraz I. Zaidi, Alison Generotti, Kevin Y. Kim, Timothy A. Herring, Sophia Reeder, Viviane M. Andrade, Karen Buttigieg, Gan Zhao, Jiun-Ming Wu, Dan Li, Linlin Bao, Jiangning Liu, Wei Deng, Chuan Qin, Ami Shah Brown, Makan Khoshnejad, Nianshuang Wang, Jacqueline Chu, Daniel Wrapp, Jason S. McLellan, Kar Muthumani, Bin Wang, Miles W. Carroll, J. Joseph Kim, Jean Boyer, Daniel W. Kulp, Laurent M. P. F. Humeau, David B. Weiner and Kate E. Broderick ()
Additional contact information
Trevor R. F. Smith: Inovio Pharmaceuticals, Plymouth Meeting
Ami Patel: Vaccine and Immunotherapy Center, Wistar Institute
Stephanie Ramos: Inovio Pharmaceuticals, Plymouth Meeting
Dustin Elwood: Inovio Pharmaceuticals, Plymouth Meeting
Xizhou Zhu: Vaccine and Immunotherapy Center, Wistar Institute
Jian Yan: Inovio Pharmaceuticals, Plymouth Meeting
Ebony N. Gary: Vaccine and Immunotherapy Center, Wistar Institute
Susanne N. Walker: Vaccine and Immunotherapy Center, Wistar Institute
Katherine Schultheis: Inovio Pharmaceuticals, Plymouth Meeting
Mansi Purwar: Vaccine and Immunotherapy Center, Wistar Institute
Ziyang Xu: Vaccine and Immunotherapy Center, Wistar Institute
Jewell Walters: Inovio Pharmaceuticals, Plymouth Meeting
Pratik Bhojnagarwala: Vaccine and Immunotherapy Center, Wistar Institute
Maria Yang: Inovio Pharmaceuticals, Plymouth Meeting
Neethu Chokkalingam: Vaccine and Immunotherapy Center, Wistar Institute
Patrick Pezzoli: Inovio Pharmaceuticals, Plymouth Meeting
Elizabeth Parzych: Vaccine and Immunotherapy Center, Wistar Institute
Emma L. Reuschel: Vaccine and Immunotherapy Center, Wistar Institute
Arthur Doan: Inovio Pharmaceuticals, Plymouth Meeting
Nicholas Tursi: Vaccine and Immunotherapy Center, Wistar Institute
Miguel Vasquez: Inovio Pharmaceuticals, Plymouth Meeting
Jihae Choi: Vaccine and Immunotherapy Center, Wistar Institute
Edgar Tello-Ruiz: Vaccine and Immunotherapy Center, Wistar Institute
Igor Maricic: Inovio Pharmaceuticals, Plymouth Meeting
Mamadou A. Bah: Vaccine and Immunotherapy Center, Wistar Institute
Yuanhan Wu: Vaccine and Immunotherapy Center, Wistar Institute
Dinah Amante: Inovio Pharmaceuticals, Plymouth Meeting
Daniel H. Park: Vaccine and Immunotherapy Center, Wistar Institute
Yaya Dia: Vaccine and Immunotherapy Center, Wistar Institute
Ali Raza Ali: Vaccine and Immunotherapy Center, Wistar Institute
Faraz I. Zaidi: Vaccine and Immunotherapy Center, Wistar Institute
Alison Generotti: Inovio Pharmaceuticals, Plymouth Meeting
Kevin Y. Kim: Vaccine and Immunotherapy Center, Wistar Institute
Timothy A. Herring: Inovio Pharmaceuticals, Plymouth Meeting
Sophia Reeder: Vaccine and Immunotherapy Center, Wistar Institute
Viviane M. Andrade: Inovio Pharmaceuticals, Plymouth Meeting
Karen Buttigieg: National Infection Service, Public Health England, Porton Down
Gan Zhao: Advaccine (Suzhou) Biopharmaceuticals Co., Ltd
Jiun-Ming Wu: Advaccine (Suzhou) Biopharmaceuticals Co., Ltd
Dan Li: Fudan University
Linlin Bao: Fudan University
Jiangning Liu: Fudan University
Wei Deng: Fudan University
Chuan Qin: Fudan University
Ami Shah Brown: Inovio Pharmaceuticals, Plymouth Meeting
Makan Khoshnejad: Vaccine and Immunotherapy Center, Wistar Institute
Nianshuang Wang: The University of Texas at Austin
Jacqueline Chu: Vaccine and Immunotherapy Center, Wistar Institute
Daniel Wrapp: The University of Texas at Austin
Jason S. McLellan: The University of Texas at Austin
Kar Muthumani: Vaccine and Immunotherapy Center, Wistar Institute
Bin Wang: Fudan University
Miles W. Carroll: National Infection Service, Public Health England, Porton Down
J. Joseph Kim: Inovio Pharmaceuticals, Plymouth Meeting
Jean Boyer: Inovio Pharmaceuticals, Plymouth Meeting
Daniel W. Kulp: Vaccine and Immunotherapy Center, Wistar Institute
Laurent M. P. F. Humeau: Inovio Pharmaceuticals, Plymouth Meeting
David B. Weiner: Vaccine and Immunotherapy Center, Wistar Institute
Kate E. Broderick: Inovio Pharmaceuticals, Plymouth Meeting

Nature Communications, 2020, vol. 11, issue 1, 1-13

Abstract: Abstract The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for the pandemic viral pneumonia disease, COVID-19. At this time, no vaccine is available to control further dissemination of the disease. We have previously engineered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein, the major surface antigen of coronaviruses, which is currently in clinical study. Here we build on this prior experience to generate a synthetic DNA-based vaccine candidate targeting SARS-CoV-2 S protein. The engineered construct, INO-4800, results in robust expression of the S protein in vitro. Following immunization of mice and guinea pigs with INO-4800 we measure antigen-specific T cell responses, functional antibodies which neutralize the SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and biodistribution of SARS-CoV-2 targeting antibodies to the lungs. This preliminary dataset identifies INO-4800 as a potential COVID-19 vaccine candidate, supporting further translational study.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-020-16505-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-16505-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-16505-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().